Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Estey

Showing results (131-140 of 204) with videos related to

Pageof 21
Sort By:
Leukemia & Lymphoma|September 24, 1999
Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phaseM Wilhelm, S O'Brien, M B Rios, et al.
Cancer|October 1, 1993
Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemiaS Suki, H Kantarjian, V Gandhi, et al.
Hematologic Pathology|January 1, 1992
AML-associated cytogenetic abnormalities (inv (16), del (16), t(8;21)) in patients with myelodysplastic syndromesE Estey, J M Trujillo, A Cork, et al.
Leukemia|July 8, 2005
Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemiaM R Ricciardi, T McQueen, D Chism, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 1996
Telomerase activity in human acute myelogenous leukemia: inhibition of telomerase activity by differentiation-inducing agentsW Zhang, M A Piatyszek, T Kobayashi, et al.
Leukemia & Lymphoma|May 1, 1993
High-dose cytosine arabinoside in chronic lymphocytic leukemia: a clinical and pharmacologic analysisL E Robertson, R Hall, M J Keating, et al.
Blood|May 1, 1992
Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSFE Estey, P F Thall, H Kantarjian, et al.
Leukemia & Lymphoma|January 28, 1999
Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemiaM Beran, E Estey, S M O'Brien, et al.
Blood|November 26, 1999
Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemiaA Aguayo, E Estey, H Kantarjian, et al.
Leukemia & Lymphoma|January 1, 1993
Treatment of myelodysplastic syndromes with AML-type chemotherapyE Estey, S Pierce, H Kantarjian, et al.
Pageof 21

Showing results (131-140 of 204) with videos related to

Sort By:
Pageof 21
Leukemia & Lymphoma|September 24, 1999
Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phaseM Wilhelm, S O'Brien, M B Rios, et al.
Cancer|October 1, 1993
Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemiaS Suki, H Kantarjian, V Gandhi, et al.
Hematologic Pathology|January 1, 1992
AML-associated cytogenetic abnormalities (inv (16), del (16), t(8;21)) in patients with myelodysplastic syndromesE Estey, J M Trujillo, A Cork, et al.
Leukemia|July 8, 2005
Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemiaM R Ricciardi, T McQueen, D Chism, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 1996
Telomerase activity in human acute myelogenous leukemia: inhibition of telomerase activity by differentiation-inducing agentsW Zhang, M A Piatyszek, T Kobayashi, et al.
Leukemia & Lymphoma|May 1, 1993
High-dose cytosine arabinoside in chronic lymphocytic leukemia: a clinical and pharmacologic analysisL E Robertson, R Hall, M J Keating, et al.
Blood|May 1, 1992
Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSFE Estey, P F Thall, H Kantarjian, et al.
Leukemia & Lymphoma|January 28, 1999
Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemiaM Beran, E Estey, S M O'Brien, et al.
Blood|November 26, 1999
Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemiaA Aguayo, E Estey, H Kantarjian, et al.
Leukemia & Lymphoma|January 1, 1993
Treatment of myelodysplastic syndromes with AML-type chemotherapyE Estey, S Pierce, H Kantarjian, et al.
Pageof 21